Financial Data and Key Metrics Changes - The company raised $4.9 million through ATM sales in the third quarter, with reported shares increasing from approximately 14.4 million in Q2 to approximately 21.8 million in Q3, a difference of 7.3 million shares [9][10] Business Line Data and Key Metrics Changes - The drug Serenity was originally approved in April 2022, with two doses approved: 120 micrograms and 180 micrograms [10] Market Data and Key Metrics Changes - There is no specific market data or key metrics changes mentioned in the provided content Company Strategy and Development Direction and Industry Competition - The company is currently in compliance with the minimum bid price requirements at the Nasdaq Capital Market and has proposed a reverse stock split as a precautionary measure to provide additional flexibility for future compliance [8][13] Management's Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook in the provided content Other Important Information - The company has approved the appointment of Ernst & Young LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2025 [13] - The advisory vote on the compensation of named executive officers has been approved [13] Q&A Session Summary Question: What was the average cost per share traded, and how many shares did the company sell? - The 14.4 million shares in Q2 were as of the filing date, not the end of the quarter, and the 21.8 million shares in Q3 were also as of the filing date, which is mid-November [9][10] Question: When was the drug Serenity approved, and how many doses have been issued? - The drug was originally approved in April 2022, with two doses approved, and there is no black box warning on the current label [10]

Financial Data and Key Metrics Changes - The company raised $4.9 million through ATM sales in the third quarter, with reported shares increasing from approximately 14.4 million in Q2 to approximately 21.8 million in Q3, a difference of 7.3 million shares [9][10] Business Line Data and Key Metrics Changes - The drug Serenity was originally approved in April 2022, with two doses approved: 120 micrograms and 180 micrograms [10] Market Data and Key Metrics Changes - There is no mention of specific market data or key metrics changes in the provided content Company Strategy and Development Direction and Industry Competition - The company is currently in compliance with the minimum bid price requirements at the Nasdaq Capital Market and has proposed a reverse stock split as a precautionary measure to provide additional flexibility for future compliance [8] Management's Comments on Operating Environment and Future Outlook - Management has indicated that they are open to communication with shareholders and are willing to address any questions through their investor relations [10] Other Important Information - The company has approved several proposals during the meeting, including the election of directors and the ratification of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2025 [13] Q&A Session Summary Question: What was the average cost per share traded, and how many shares did the company sell? - The company clarified that the 14.4 million shares in Q2 were as of the filing date, not the end of the quarter, and that the 21.8 million shares in Q3 were also as of the filing date [9][10] Question: When was the drug Serenity approved, and does it have a black box warning? - The drug Serenity was approved in April 2022, with no black box warning on the current label [10]

Core Points - Diamond Estates Wines & Spirits Inc. has entered into a Seventh Amendment to its Second Amended and Restated Credit Agreement with Bank of Montreal, effective November 10, 2025 [1] - The company expresses gratitude to Bank of Montreal for its support during its financial turnaround, as indicated by its Fiscal 2024/25 year-end and Q1 results [2] - The company will release its Q2 results towards the end of November [2] Company Overview - Diamond Estates Wines & Spirits Inc. produces high-quality wines and ciders and acts as a sales agent for over 120 beverage alcohol brands across Canada [3] - The company operates four production facilities, three in Ontario and one in British Columbia, producing predominantly VQA wines under various well-known brand names [3] Product Portfolios - The wine portfolio includes renowned brands such as Fat Bastard, Gabriel Meffre, and Kaiken, among others from various countries [5] - The spirits portfolio features distinguished brands like Tag Vodka, Ginslinger Gin, and Barnburner Whisky, as well as international brands from Mexico, Scotland, and the UK [6] - The beer, cider, and ready-to-drink (RTD) portfolio includes products from Ontario and international brands from Belgium, the Netherlands, and Germany [7] Credit Facilities - A bulge amount credit facility of $3,600,000 has been established, maturing on the earlier of the cancellation request date or March 27, 2026 [9] - A limited recourse guarantee has been added, granted by Lassonde Industries Inc. in favor of BMO, not exceeding the outstanding Bulge Amount [9] - Interest rates have been amended to Prime Rate plus 2.65% during the Temporary Bulge Period and Prime Rate plus 2.40% at all other times [9]

Company Announcements - Diamond Estates Wines & Spirits Inc. has issued 248,683 deferred share units (DSUs) to non-executive directors at a deemed price of $0.19 per DSU, totaling $47,250 in deferred compensation [1] - The company has granted 600,000 share options to Basman Alias, the new Chief Financial Officer, at a strike price of $0.19 per share option, which are exercisable for five years and vest at 25% annually [2][3] Strategic Insights - The share option grants are indicative of the key role Basman Alias plays in executing Diamond Estates' strategic plan, emphasizing the alignment of management success with shareholder interests [3] Upcoming Events - The company encourages shareholders to vote in advance of the upcoming shareholder meeting on October 30, 2025, due to ongoing Canada Post service disruptions, with proxy votes required by October 28, 2025 [3] Company Overview - Diamond Estates is a producer of high-quality wines and ciders, operating four production facilities in Canada and representing over 120 beverage alcohol brands [4][5]